Abstract
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conducted a 12-month longitudinal study by collecting 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China. The study tested specific antibody responses, revealing that the positive rate of IgG antibody against the receptor-binding domain of the spike protein (RBD-IgG) exceeded 70% for 12 months post-diagnosis. While RBD-IgG levels decreased over time, titers stabilized at approximately 64.3% of the initial level by the ninth month. Furthermore, male donors produced higher RBD-IgG levels than females, and patient age correlated positively with RBD-IgG titers. A strong positive correlation between RBD-IgG and neutralizing antibody titers was also identified, providing critical insights into SARS-CoV-2-induced immune memory for vaccine and therapy development.
Introduction
In the early stages of the COVID-19 pandemic, a critical unknown was the longevity of natural immunity. While historical data from SARS-CoV-1 suggested that antibodies could last approximately two years before significantly waning, early data for SARS-CoV-2 was limited to short-term windows of three to six months. Understanding the long-term kinetics of the humoral response is essential for predicting reinfection risks and informing vaccine strategies, as most vaccines target the same Spike protein regions as natural infection.
Methods and Materials
This longitudinal study screened 869 convalescent donors in Wuhan, China, resulting in 1,782 plasma samples collected between February 2020 and January 2021. The research team employed several analytical methods:
- RBD-IgG ELISA: A CE-marked enzyme-linked immunosorbent assay (ELISA) was used to quantify antibodies specifically targeting the Receptor-Binding Domain (RBD) of the Spike protein.
- Neutralization Assays (PRNT): To verify the functional capacity of these antibodies, Plaque Reduction Neutralization Tests (PRNT) were performed on a subset of 150 samples. This is considered the "gold standard" for measuring an antibody's ability to block viral entry into cells.
- Statistical Stratification: The researchers analyzed variables including age, gender, and ABO blood type across three stages: early (1-2 months), middle (6-7 months), and late (11-12 months) post-diagnosis.
Key Insights
The Nine-Month Plateau
A primary finding of this study is that antibody decay does not follow a continuous downward trajectory. The Geometric Mean Titer (GMT) dropped initially but stabilized at approximately 64.3% of the initial level by the ninth month. This stabilization likely indicates a transition from short-lived effector B cells to long-lived bone marrow plasma cells (BMPCs), which provide a steady, long-term supply of antibodies.
Demographic Influences: Age and Gender
The study observed that male donors and older individuals (within the 18–55 age range) tended to have higher initial antibody titers. This may reflect the fact that these groups often experience more robust initial infections, which paradoxically triggers a stronger and more persistent immune memory response.
RBD-IgG as a Neutralization Proxy
The researchers identified a strong positive correlation (r=0.703) between RBD-IgG titers and actual neutralizing activity. This finding validates the use of more accessible and cost-effective ELISA tests for large-scale immunity monitoring and population-level screening.
Blood Type Neutrality
While some research suggests that certain blood types (such as Type A) may be more susceptible to contracting COVID-19, this study found that once infected, ABO blood type had no significant impact on the strength or duration of the subsequent antibody response.
Results
- Persistence: The positive rate for RBD-IgG remained high throughout the study, starting at 94.6% at 1-2 months and maintaining 81.2% at 11-12 months.
- Titer Stabilization: The GMT began at 628 (month 1) and reached a plateau between 189 and 200 from month 9 through month 12.
- Gender Dimorphism: Male donors produced significantly more RBD-IgG than females in the early stages (p<0.0001), though the gap narrowed as the titers stabilized.
- Individual Variation: In a subset of low-titer donors (approximately 11.6%), antibody levels showed a slight increase between months 10 and 11, which the authors attribute to "delayed seroconversion."
Discussion and Limitations
While these results offer an optimistic view of immune durability, several limitations remain. The study was restricted to plasma donors aged 18–55, meaning the kinetics in pediatric or geriatric populations remain uncharacterized. Additionally, the study focused on the original SARS-CoV-2 strain; the emergence of immune-evasive variants may alter the neutralization efficacy of these antibodies. Finally, this research focused exclusively on humoral immunity (antibodies) and did not measure T-cell responses, which constitute a vital and often longer-lasting arm of the immune system.
Future research is required to determine if the 12-month stabilization observed in natural infection is mirrored in vaccine-induced immunity and how this protection holds up against evolving viral variants.
Summary updated